Structure TherapeuticsGPCR
About: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Employees: 163
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
63% more call options, than puts
Call options by funds: $28.1M | Put options by funds: $17.3M
28% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 50
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
2% more funds holding
Funds holding: 160 [Q3] → 163 (+3) [Q4]
0.51% less ownership
Funds ownership: 35.81% [Q3] → 35.3% (-0.51%) [Q4]
29% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 5 (-2) [Q4]
39% less capital invested
Capital invested by funds: $2.69B [Q3] → $1.64B (-$1.04B) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Citizens Capital Markets Jonathan Wolleben 33% 1-year accuracy 23 / 69 met price target | 300%upside $87 | Market Outperform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 6 articles about GPCR published over the past 30 days
